Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.51 |
| ▸ | FLT3 | P36888 | 8/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 8/20 | 0.51 |
| ▸ | CSF1R | P07333 | 7/20 | 0.51 |
| ▸ | BLK | P51451 | 6/20 | 0.51 |
| ▸ | LCK | P06239 | 7/20 | 0.46 |
| ▸ | FLT1 | P17948 | 6/20 | 0.46 |
| ▸ | FLT4 | P35916 | 6/20 | 0.46 |
| ▸ | LYN | P07948 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 2/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041771 | 0.93 | KDR (0.47) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041775 | 0.91 | CSF1R (0.49) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041772 | 0.91 | CSF1R (0.49) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041777 | 0.91 | KIT (0.49) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041755 | 0.91 | CSF1R (0.53) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041778 | 0.90 | KIT (0.52) | KDRFLT3PDGFRBKITCSF1R | |
| SCHEMBL13041768 | 0.90 | CSF1R (0.52) | KDRFLT3KITCSF1RBLK | |
| SCHEMBL13041752 | 0.90 | KDR (0.54) | KDRFLT3KITCSF1RBLK | |
| SCHEMBL13041774 | 0.89 | KIT (0.50) | KDRFLT3KITCSF1RBLK | |
| SCHEMBL13077903 | 0.88 | KIT (0.48) | KDRFLT3PDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825114-B2 | Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER SCHERING PHARMA AG (DE) | 2010-11-02 | — | — | US | disclosed |
| US-20090018129-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-01-15 | — | — | US | disclosed |
| WO-2007144202-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-1867647-A1 | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018129-A1 | SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | KDR, TIE1, TEK | KDR 1/4885FLT3 116/4885PDGFRB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.